Introduction {#s0001}
============

Non-small cell lung cancer (NSCLC) as the most common type of lung cancer has been the leading cause of cancer-related death worldwide.[@cit0001],[@cit0002] Currently, various therapeutic strategies including radiation, chemotherapy, neoadjuvant chemotherapy, and surgery separately or in combination are widely applied in the therapy of NSCLC.[@cit0003] Fortunately, many patients obtain unprecedented survival benefits from the clinical use of small molecule tyrosine kinase inhibitors and immunotherapy.[@cit0004] Despite significant advancements in NSCLC treatment being achieved over the past two decades, the overall cure and 5-year survival rates for NSCLC remain low, especially in metastatic lung cancer.[@cit0005],[@cit0006] Thus, understanding of the pathogenic mechanisms of NSCLC progression and finding novel therapeutic targets are required to expand the clinical benefit to a broader patient population.

Long non-coding RNAs (lncRNAs) are increasingly implicated as gene regulators in diverse diseases.[@cit0007]--[@cit0009] Notably, lncRNAs are considered to play important roles in disease progression of various tumors, such as NSCLC, breast cancer, gastric cancer, bladder cancer, and many other cancer types.[@cit0010],[@cit0011] Accordingly, wide-range evidences have demonstrated that lncRNAs are emerging as the potential therapeutic target for cancer patients.[@cit0012],[@cit0013] More recently, T-box transcription factor 5 (*TBX5*) serves as a novel tumor suppressor gene in the disease progression.[@cit0014] *TBX5* antisense RNA 1 (*TBX5-AS1*), a newly discovered lncRNA, is the tail-to-tail antisense of *TBX5*.[@cit0015] It is worth noting that *TBX5-AS1* may be associated with the prognosis of patients with lung squamous cell carcinoma (LUSC).[@cit0016] In addition, Zhang et al also reported the *TBX5-AS1* might have an effect on the regulation of lung adenocarcinoma development.[@cit0017] With these evidences, we supposed that *TBX5-AS1* might be involved in the progression of NSCLC and had the potential to be a potent therapeutic target for NSCLC therapy.

The phosphatidylinositol 3-kinase (PI3K)/AKT pathway is recognized as a pivotal signaling pathway in carcinogenesis and regulates various key cellular functions, such as proliferation, survival, and metabolism.[@cit0018],[@cit0019] Genes in this pathway are the most frequently amplified, mutated, and translocated in human cancers.[@cit0020] Research shows that aberrant activation of the PI3K/AKT pathway is associated with tumor genesis, cancer progression, and drug resistance.[@cit0021] Previously, *TBX3* as another member of TBX family was found to be associated with the PI3K/AKT pathway.[@cit0022] Moreover, it is demonstrated that TBX1 functions as a tumor suppressor in thyroid cancer by inhibiting activation of the PI3K/AKT pathway.[@cit0023] Therefore, we speculated that *TBX5-AS1* might participate in NSCLC progression through the PI3K/AKT pathway. However, no evidence demonstrated the role and regulatory pathway of *TBX5-AS1* in NSCLC progression. Thus, in the present study, we detected the aberrant expression of *TBX5-AS1* in NSCLC and further verified its effects on aggressive phenotypes of NSCLC cells. More importantly, the regulation effect of *TBX5-AS1* on the PI3K/AKT pathway was innovatively studied in vitro.

Materials and Methods {#s0002}
=====================

Clinical Samples {#s0002-s2001}
----------------

Ninety-six pairs of NSCLC tissues and para-carcinoma normal tissues were originally obtained from 96 patients with NSCLC in our hospital, between January 2018 and December 2019. In addition, the plasma samples were respectively collected from 96 NSCLC patients and 96 healthy volunteers. All enrolled patients did not receive surgery, radiotherapy, or chemotherapy before tissue/serum collection. All clinical samples were immediately frozen in liquid nitrogen and stored at −80 °C in a refrigerator until the analysis of *TBX5-AS1* expression. All protocols have been approved by the Ethics Committee of Weifang Yidu Center Hospital and performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants.

Cell Lines and Cell Culture {#s0002-s2002}
---------------------------

The human bronchial epithelioid cell line (16HBE) and human lung cancer cell lines (A549, H1299 and NCI-H520) were originally obtained from American Type Culture Collection (ATCC; Manassas, VA, USA). All cell lines were maintained in RPMI-1640 medium (Thermo Fisher Scientific, Cambridge, MA, USA) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/mL), and streptomycin (100 μg/mL). Cell lines were incubated in a humidified incubator at 37 °C with a 5% CO~2~ atmosphere.

RNA Extraction and qRT-PCR {#s0002-s2003}
--------------------------

Total RNA from tumor tissues and cell lines was prepared using TRIzol^®^ reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Total RNA from plasma was extracted using TRIzol LS Reagent (Invitrogen) according to the manufacturer's protocol. A NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA) was used to determine the purity and concentration of RNA, and agarose gel electrophoresis was used to assess the integrity of RNA. The samples with absorbance ratios 260/280 (1.8--2.0) and 260/230 (1.9--2.2) were considered for inclusion in the study. Subsequently, the reverse transcription of RNA to cDNA was performed using Reverse Transcription System (Promega Corporation, Madison, WI, USA) following the manufacturer's protocol. Finally, the qRT-PCR assays were carried out on an ABI 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using the SYBR PrimeScript RT-PCR Kit (Takara Bio, Dalian, China). The relative expression level was analyzed using the comparative cycle threshold (CT) (2^−ΔΔCT^) method, using β-actin as the endogenous control. PCR primer sequences were listed as follows: 1) *TBX5-AS1* forward 5ʹ-GCAAAACGTACCGCGTAGAC-3ʹ and reverse 5ʹ-GATGCCGGAGAAAGGAACCA-3ʹ; and 2) β-actin forward 5ʹ- CACCATTGGCAATGAGCGGTTC-3ʹ and reverse 5ʹ-AGGTCTTTGCGGATGTCCACGT-3ʹ.

Cell Transfection {#s0002-s2004}
-----------------

All transfections were performed using the Lipofectamine 2000 Transfection Kit (Invitrogen) according to the manufacturer's instruction. The knockdown of *TBX5-AS1* in NCI-H520 cells was induced by small interfering RNA (siRNA) targeting *TBX5-AS1* (si-TBX5-AS1), using scramble siRNA as a negative control (si-NC). Besides, human *TBX5-AS1* cDNA insert was cloned into the pcDNA3.1 plasmid (Invitrogen) to construct a recombinant plasmid vector with the *TBX5-AS1* gene (pcDNA3.1-TBX5-AS1). Then, pcDNA3.1-TBX5-AS1 was used to induce the overexpression of *TBX5-AS1* in A549 cells, using pcDNA3.1 plasmid as a negative control (pcDNA3.1-NC). After transfection, the aberrant expression of *TBX5-AS1* was verified by qRT-PCR.

MTT Assay {#s0002-s2005}
---------

Cell proliferation was evaluated by MTT assay using the Cell Proliferation Reagent Kit I (Roche, Basel, Switzerland) according to the manufacturer's protocol. Briefly, the prepared cells (1×10^4^ cells/well) were seeded into 96-well plates and incubated for 0, 1, 2, 3, 4 d at 37 °C with a 5% CO~2~ atmosphere. After the incubation, 10 μL MTT solution was added into each well, followed by incubation for another 4 h. Then, the medium was removed and 100 μL solubilization solution was added into each well and incubated overnight. Finally, the absorbance value was detected at 450 nm using a microplate reader (BioRad, Hercules, CA, USA).

Colony Formation Assay {#s0002-s2006}
----------------------

Colony formation ability was evaluated using the standard two-layer soft agar culture.[@cit0024] In brief, the prepared cells were seeded in the 24-well culture plates at a density of 200 cells/well. Then, cells were maintained in RPMI-1640 medium with 0.6% agarose underlay. After incubation for 14 days, the surviving colonies were fixed with 3.7% acetic acid methanol and then stained with 0.1% crystal violet. Finally, the stained colonies were manually counted and visualized under a microscope (Olympus, Tokyo, Japan).

Cell Migration and Invasion Assay {#s0002-s2007}
---------------------------------

Cell migration ability was evaluated using a wound-healing assay. The prepared cells were seeded on a 6-well plate in RPMI-1640 medium supplemented with 10% FBS and cultured to at least 90% confluence. Then, cells were starved in serum-free RPMI-1640 and cultured for another 24 h. Subsequently, the monolayer cells were scraped with a 10 µL plastic pipette tip in the middle of a culture plate to make a "Scratch" wound and washed with serum-free medium. At 0 and 48 h after scratching, images of the wounded area were collected by an inverted phase contrast microscope (magnification: 10× objective; Olympus, Tokyo, Japan). The rate of wound area was calculated relative to the initial wound area. After pretreating confluent cell monolayers (si1-TBX5-AS1 and pcDNA3.1-TBX5-AS1) with mitomycin C (MMC, 5 μM; Wako Pure Chemicals Ltd., Osaka, Japan) for 2 h, wound-healing assays were also performed.

Cell invasion ability was evaluated using a Matrigel-coated Transwell chamber (BD Biosciences, San Jose, CA, USA). Briefly, the prepared cells were pre-starved in serum-free medium for 24 h and then incubated in the upper chamber of a Matrigel-coated Transwell (8 μm) for 48 h. RPMI-1640 containing 10% FBS was added into the lower chamber of Transwell. After incubation for 24 h, non-invading cells were removed from the upper surface of the Matrigel. Finally, the lower side of the upper chamber was fixed with cold methanol for 30 min and then stained with 4,6-diamidino-2-phenylindole (Sigma Aldrich, St. Louis, MO, USA). Images were photographed under a microscope (magnification: 400× objective; Olympus, Tokyo, Japan).

Flow Cytometry Assay {#s0002-s2008}
--------------------

Cell apoptosis was evaluated by flow cytometry assay using the Annexin V-fluorescein isothiocyanate (FITC) apoptosis kit (BD Biosciences, San Jose, CA, USA). The prepared cells were double-labeled with Annexin V-FITC (5 μL) and propidium iodide (5 μL) for 15 min following the manufacturer's protocol. The apoptosis rate was immediately analyzed in a FACSAria™ Fusion flow cytometer using CellQuest software (BD Biosciences, San Jose, CA, USA).

Western Blot {#s0002-s2009}
------------

Whole-cell lysates were lysed from cell lines using RIPA buffer (Thermo Scientific, USA). The concentration of lysates was quantified using the Bicinchoninic Acid protein assay kit (Thermo Fisher Scientific, Cambridge, MA, USA). An equal amount of proteins (50 μg) was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto the polyvinylidene fluoride (PVDF) membranes (Millipore, USA). After blocking with 5% (w/v) skim milk, the blotting PVDF membranes were separately incubated with specific primary antibodies against Bcl-2, 4223; Bax, 14,796; p-PI3K, 17,366; (1:1000, Cell Signaling Technology, USA), PI3K, ab32089; AKT, ab8805; GAPDH, ab181606 (1/1000, Abcam, USA), and p-AKT, SAB4301414 (1:1000, Sigma-Aldrich, USA) overnight at 4 °C. Subsequently, PVDF membranes were blocked with goat anti-rabbit IgG HRP-linked secondary antibody (1:5000, Abcam) at room temperature for 1 h. The signal bands were measured with an Enhanced Chemiluminescence Kit (Thermo Fisher Scientific, Cambridge, MA, USA) and the band intensity was analyzed by Quantity One software (BioRad, Hercules, CA, USA).

Statistical Analysis {#s0002-s2010}
--------------------

Statistical analysis was analyzed by GraphPad Prism 7 software and SPSS software version 22.0 (IBM Corporation, Armonk, NY, USA). For in vitro experiments, all experiments were repeated in triplicate and the results were expressed as the mean±standard deviation (SD). Student's *t*-test or one-way ANOVA followed by Tukey's multiple comparisons test was performed to analyze the statistical differences between two or among multiple groups. The association between expression level of *TBX5-AS1* and clinicopathological parameters of patients were analyzed using the chi-square test. Distinguishing performance of the *TBX5-AS1* was assessed by constructing a receiver operating characteristic (ROC) curve and evaluated by calculating the area under curve (AUC). *p*\<0.05 was considered statistically significant.

Results {#s0003}
=======

*TBX5-AS1* Expression is Down-Regulated in NSCLC and Associated with Progression of NSCLC {#s0003-s2001}
-----------------------------------------------------------------------------------------

Lung adenocarcinoma (LUAD) is one of the common types of NSCLC. In the light of the data from TCGA, we found that *TBX5-AS1* expression in LUAD tissues was lower than that of normal tissues (*p*\<0.01, [Figure 1A](#f0001){ref-type="fig"}). Moreover, the Kaplan--Meier survival analysis showed that the overall survival in patients with low *TBX5-AS1* expression was poorer than that of patients with high *TBX5-AS1* expression (*p*=0.02, [Figure 1B](#f0001){ref-type="fig"}). These data indicated that *TBX5-AS1* might be correlated with prognosis in NSCLC. To determine the involvement of *TBX5-AS1* in the progression of NSCLC, we firstly detected the expression of *TBX5-AS1* in tissues, cell lines, and plasma, respectively. As shown in [Figure 1C](#f0001){ref-type="fig"} and [E](#f0001){ref-type="fig"} ([[Supplementary Table-1](https://www.dovepress.com/get_supplementary_file.php?f=255195.doc)]{.ul}) ([[Supplementary Table-2](https://www.dovepress.com/get_supplementary_file.php?f=255195.doc)]{.ul}), the expression level of *TBX5-AS1* both in tissues and plasma from NSCLC patients were reduced compared to the normal and control (*p*\<0.01). Similarly, a lower expression of *TBX5-AS1* was observed in NSCLC cell lines (A549, NCI-H520, and H1299) compared to 16HBE cells (*p*\<0.01, [Figure 1D](#f0001){ref-type="fig"}). Furthermore, to evaluate the clinical significance of *TBX5-AS1* in NSCLC, we assessed its diagnostic performance and the association with pathological parameters. ROC analysis demonstrated that the AUC for the *TBX5-AS1* level in discrimination between NSCLC and healthy volunteers was 0.6498 (*p*=0.0003, [Figure 1F](#f0001){ref-type="fig"}), indicating a favourable distinguishing performance of *TBX5-AS1* for NSCLC. The chi-square test showed that the *TBX5-AS1* expression level was significantly associated with lymph node metastasis (*p*=0.002) and histological grade (*p*=0.004), but not associated with gender, age, and tumor size ([Table 1](#t0001){ref-type="table"}). Taken together, the results suggested that the down-regulation of *TBX5-AS1* might play an important role in the progression of NSCLC.Table 1Association Between *TBX5-AS1* Expression and Clinicopathological Parameters of NSCLC PatientsClinicopathological ParametersNo. of Cases*TBX5-AS1* Expression*p* valueHighLow**Gender**0.22 Male502822 Female462026**Age (years)**0.837 \<60552827 ≥60412021**Tumor size (cm)**0.200 \<3342014 ≥3622834**Lymph node metastasis**0.002\*\* No453015 Yes511833**Histological grade**0.004\*\* I523319 II--III441529[^2] Figure 1TBX5-AS1 expression was down-regulated in patients with NSCLC and NSCLC cell lines. (**A**) TBX5-AS1 expression in LUAD tissues and normal tissues was analyzed by TCGA data. (**B**) Survival analysis based on TCGA data. (**C**) The mRNA expression of TBX5-AS1 in tumor tissue and para-carcinoma tissues (n=96) from patients with NSCLC was detected by qRT-PCR; Student's *t*-test was used for comparison between the two groups, *\*\*p*\<0.01 vs Normal. (**D**) The mRNA expression of TBX5-AS1 in the bronchial epithelioid cell line (16HBE) and lung cancer cell lines (A549, H1299 and NCI-H520) was detected by qRT-PCR; one-way ANOVA followed by Tukey's multiple comparisons test was used for among multiple groups, \*\**p*\<0.01 vs 16HBE. (**E**) The mRNA expression of TBX5-AS1 in plasma from NSCLC patients and healthy volunteers (n=96) was detected by qRT-PCR; Student's *t*-test was used for comparison between the two groups, \*\**p*\<0.01 vs Control group. (**F**) Receiver operating characteristic curves for TBX5-AS1 expression levels to discriminate NSCLC patients from healthy volunteers; the cut-off value was 0.725 with sensitivity of 40.63% and specificity of 82.29%, and the AUC was 0.6498.

*TBX5-AS1* Inhibits the Proliferation of NSCLC Cells {#s0003-s2002}
----------------------------------------------------

To confirm the role of *TBX5-AS1* in the progression of NSCLC, *TBX5-AS1* was knocked down or overexpressed in two NSCLC cells, respectively. The expression of *TBX5-AS1* was confirmed by qRT-PCR after transfection. As shown in [Figure 2A](#f0002){ref-type="fig"}, the expression of *TBX5-AS1* was successfully reduced in NCI-H520 cells (*p*\<0.01) and up-regulated in A549 cells (*p*\<0.01). Then, the MTT assay was performed to evaluate the effects of *TBX5-AS1* on cell viability. The results showed that the cell viability was significantly enhanced by the inhibition of *TBX5-AS1*, while decreased by the overexpression of *TBX5-AS1* (*p*\<0.01, [Figure 2B](#f0002){ref-type="fig"}). Furthermore, we also measured the colony formation ability of NSCLC cells after transfection. [Figure 2C](#f0002){ref-type="fig"} reveals similar results with the MTT assay, the colony formation ability of NSCLC cells was promoted by the inhibition of *TBX5-AS1* (*p*\<0.01) while suppressed by the overexpression of *TBX5-AS1* (*p*\<0.01). Overall, these results indicated that *TBX5-AS1* significantly inhibited the cell proliferation in NSCLC cell lines.Figure 2TBX5-AS1 inhibited the proliferation of NSCLC cells. (**A**) NHC-H520 cells were transfected with siRNA-TBX5-AS1, and A549 cells were transfected with pcDNA3.1-TBX5-AS1. After transfection for 48 h, TBX5-AS1 expression in NCI-H520 and A549 cells was determined by qRT-PCR. (**B**) After transfection for 0, 1, 2, 3, 4 days, cell viability of NCI-H520 and A549 cells was measured by MTT assay. (**C**) After transfection, cell proliferation of NCI-H520 and A549 cells was measured by colony formation assay. All results were expressed as mean±SD. One-way ANOVA followed by Tukey's multiple comparisons test was used for among multiple groups, \**p*\<0.05, \*\**p*\<0.01 vs Control, si-NC, pcDNA3.1-NC group.

*TBX5-AS1* Inhibits the Migration and Invasion of NSCLC Cells {#s0003-s2003}
-------------------------------------------------------------

To further verify the effects of *TBX5-AS1* on the aggressive phenotype of NSCLC cells, the wound-healing assay and Transwell assay were respectively used to assess the cell migration and invasion ability. We found that cell migration ability (wound healing rate) of NSCLC cells was significantly enhanced by the down-regulation of *TBX5-AS1* (*p*\<0.01), while suppressed by the up-regulation of *TBX5-AS1* (*p*\<0.01, [Figure 3A](#f0003){ref-type="fig"}). To assess whether wound healing was due to cell migration instead of cell proliferation, we detected the wound healing in the transfected group (si1-TBX5-AS1 and pcDNA3.1-TBX5-AS1) and the transfection group with mitomycin C (MMC, an inhibitor of proliferation). Our data showed the wound healing rate in the transfected group was slightly higher than that in the transfection group with MMC (si1-TBX5-AS1+MMC and pcDNA3.1-TBX5-AS1+MMC), but there was no significant difference ([[Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=255195.doc)]{.ul}). Therefore, *TBX5-AS1* regulated wound healing by cell migration regardless of proliferation. Moreover, we also found that cell invasion ability of NSCLC cells was enhanced by the down-regulation of *TBX5-AS1* (*p*\<0.01), while suppressed by the up-regulation of *TBX5-AS1* (*p*\<0.01, [Figure 3B](#f0003){ref-type="fig"}). Overall, these results indicated that *TBX5-AS1* significantly inhibited the migration and invasion of NSCLC cell lines in vitro.Figure 3TBX5-AS1 inhibited the migration and invasion of NSCLC cells. (**A**) After transfection, cell migration of NCI-H520 and A549 cells was detected by wound-healing assay. (**B**) After transfection, cell invasion of NCI-H520 and A549 cells was detected by Transwell assay. Scale bars, 100 μm. All results were expressed as mean±SD. One-way ANOVA followed by Tukey's multiple comparisons test was used for among multiple groups, \*\**p*\<0.01 vs Control, si-NC, pcDNA3.1-NC group.

*TBX5-AS1* Induces Apoptosis of NSCLC Cells {#s0003-s2004}
-------------------------------------------

We also assessed the effects of *TBX5-AS1* on cell apoptosis using flow cytometry assay. As shown in [Figure 4A](#f0004){ref-type="fig"}, the apoptosis rate of NSCLC cells was significantly decreased by the down-regulation of *TBX5-AS1* compared to controls (*p*\<0.01), while increased by the up-regulation of *TBX5-AS1* (*p*\<0.01). To further verify the effects of *TBX5-AS1* on apoptosis, the expression levels of apoptosis-related proteins Bax and Bcl-2 were detected. Western blot assay demonstrated that the down-regulation of *TBX5-AS1* in NSCLC cells significantly inhibited Bax expression (*p*\<0.01) and enhanced Bcl-2 expression (*p*\<0.01, [Figure 4B](#f0004){ref-type="fig"}). Conversely, the up-regulation of *TBX5-AS1* significantly increased Bax expression (*p*\<0.01) and suppressed Bcl-2 expression (*p*\<0.01, [Figure 4B](#f0004){ref-type="fig"}). Overall, these results suggested that *TBX5-AS1* significantly induced apoptosis and pro-apoptotic protein expression, while it inhibited the anti-apoptotic protein expression in NSCLC cell lines.Figure 4TBX5-AS1 induced apoptosis of NSCLC cells. (**A**) After transfection, cell apoptosis of NCI-H520 and A549 cells was evaluated by flow cytometry assay. (**B**) After transfection, the expression of apoptosis-related proteins (Bax and Bcl-2) in NCI-H520 and A549 cells was analyzed using western blot analysis, GADPH as an endogenous control. All results were expressed as mean±SD. One-way ANOVA followed by Tukey's multiple comparisons test was used for among multiple groups, \*\**p*\<0.01 vs Control, si-NC, pcDNA3.1-NC group.

*TBX5-AS1* Inhibits the Aggressive Phenotypes of NSCLC Cells Through Inactivating the PI3K/AKT Pathway {#s0003-s2005}
------------------------------------------------------------------------------------------------------

To confirm the hypothesis that *TBX5-AS1* regulates the PI3K/AKT pathway, we measured the expression levels of PI3K and AKT in transfected NSCLC cells. As shown in [Figure 5A](#f0005){ref-type="fig"}, the knockdown of *TBX5-AS1* in NCI-H520 cells obviously stimulated the phosphorylation of PI3K and AKT (*p*\<0.01). Inversely, the *TBX5-AS1* overexpression in A549 cell suppressed the phosphorylation of PI3K and AKT (*p*\<0.01, [Figure 5B](#f0005){ref-type="fig"}).Figure 5TBX5-AS1 inhibited the activation PI3K/AKT pathway in NSCLC cells. (**A**) si-TBX5-AS1 or (**B**) pcDNA3.1-TBX5-AS1 was transfected into NCI-H520 or A549 cells. Then, the expression of PI3K/AKT pathway-related proteins (p-PI3K, PI3K, p-AKT, and AKT) were measured by western blot, with GADPH acting as the endogenous control. All results were expressed as mean±SD. One-way ANOVA followed by Tukey's multiple comparisons test was used for among multiple groups, \*\**p*\<0.01 vs Control, si-NC, pcDNA3.1-NC group.

Subsequently, in order to further confirm the molecular mechanism of *TBX5-AS1* in the PI3K/AKT pathway, the PI3K activator (740Y-P) was used to treat the pcDNA3.1-*TBX5-AS1* transfected cells. Firstly, western blot assay showed that the addition of 740Y-P in transfected cells reversed the inhibition of PI3K and AKT phosphorylation caused by *TBX5-AS1* overexpression (*p*\<0.01, [Figure 6A](#f0006){ref-type="fig"}), confirming the 740Y-P-induced activation of the PI3K/AKT pathway. Then, we detected the influences of 740Y-P on the phenotypes of transfected cells, including colony formation, migration, invasion, and apoptosis. The results showed that the addition of 740Y-P significantly reversed the *TBX5-AS1*-induced inhibition on colony formation, migration, and invasion (*p*\<0.05, [Figure 6B](#f0006){ref-type="fig"}--D). Besides, the flow cytometry assay demonstrated that the *TBX5-AS1*-induced apoptosis was alleviated by 740Y-P treatment (*p*\<0.01, [Figure 6E](#f0006){ref-type="fig"}). Overall, these results suggested that *TBX5-AS1* inhibited the aggressive phenotypes of NSCLC cells through inactivating the PI3K/AKT pathway.Figure 6TBX5-AS1 inhibited the aggressive phenotypes of NSCLC cells through inactivating the PI3K/AKT pathway. The pcDNA3.1-TBX5-AS1 transfected A549 cells were exposed to PI3K activator (740Y-P) or not. (**A**) After treatment, the expression of PI3K/AKT pathway-related proteins (p-PI3K, PI3K, p-AKT, and AKT) was measured by western blot. (**B**) Cell proliferation was measured by colony formation assay. (**C**) Cell migration was detected by wound-healing assay. (**D**) Cell invasion was detected by Transwell assay. (**E**) Cell apoptosis was evaluated by flow cytometry assay. All results were expressed as mean±SD. One-way ANOVA followed by Tukey's multiple comparisons test was used for among multiple groups, \*\**p*\<0.01 vs Control group; ^\#^*p*\<0.01, ^\#\#^*p*\<0.01 vs pcDNA3.1-TBX5-AS1 group.

Discussion {#s0004}
==========

Despite significant developments in the targeted therapies for NSCLC, the prognosis for advanced stage patients remains dismal. Hence, further elaboration of the underlying pathogenic mechanisms for NSCLC progression remains the research challenge.[@cit0006] In recent years, lncRNAs have been proven to function as tumor suppressors or oncogenes in various tumors.[@cit0025] Whereas, the lncRNA profiles are extremely complicated and not yet fully elucidated. Thus, the discovery of new lncRNAs will probably change the landscape of cancer genetics and potentially become effective therapeutic targets. Herein, this ground-breaking study identified *TBX5-AS1* as a suppressor lncRNA in NSCLC for the first time. We verified the down-regulation of *TBX5-AS1* and its association with the progression of NSCLC. More importantly, the present study indicated that *TBX5-AS1* inhibited the aggressive phenotypes of NSCLC cells through inactivating the PI3K/AKT pathway.

Numerous studies have proved that lncRNAs play major roles in the gene regulation and thus influence the diverse aspects of cellular homeostasis, including survival, proliferation, or genomic stability.[@cit0026] The aberrant expression of several lncRNAs is associated with malignant transformation and poor prognosis of cancers.[@cit0027] *TBX5-AS1*, a novel cancer-related lncRNA, is the antisense RNA of *TBX5*. A previous bioinformatics analysis revealed that *TBX5-AS1* was significantly down-regulated in female lung cancer tissue.[@cit0028] Hereby, we detected the differential expression of *TBX5-AS1* in clinical samples and cell lines. The results demonstrated that *TBX5-AS1* was down-regulated in NSCLC patients and cell lines, which was identified with the previous analysis.[@cit0028] Furthermore, using a cohort of NSCLC patients, the clinical relationship analysis showed that *TBX5-AS1* expression was closely associated with lymph node metastasis and histological grade, suggesting that the down-regulation of *TBX5-AS1* led to a poorer clinical outcome. Similarly, a bioinformatics analysis has also reported that *TBX5-AS1* may be associated with the prognosis of patients with LUSC.[@cit0016] It is evident that our present findings provide new evidence supporting this preliminary analysis. In addition to the analysis in lung cancer, *TBX5-AS1* is observed to shorten the relapse-free survival of breast cancer patients.[@cit0029] Based on the evidence above, we concluded that *TBX5-AS1* was involved in the progression of NSCLC.

However, the understanding of *TBX5-AS1* in cancer still formed at the level of bioinformatics analysis using the existing database[@cit0016],[@cit0028],[@cit0029] and thus further experimental research is still needed. LncRNAs could serve as competitive endogenous RNAs (ceRNAs) by sponging the endogenous suppressive effects of microRNAs or RNA-binding proteins (RBPs) on their targeted transcripts.[@cit0030],[@cit0031] Given these biological characteristics of lncRNAs, we validated the effect of *TBX5-AS1* on various aspects of cell phenotypes, including survival, proliferation, migration, invasion, and apoptosis. As expected, *TBX5-AS1* affected the cell phenotypes in multiple NSCLC cell lines. The overexpression of *TBX5-AS1* inhibited the cell viability, colony formation, migration, and invasion, while it promoted the apoptosis. Conversely, knockdown of *TBX5-AS1* showed the completely opposite results. To our knowledge, no previous study has investigated the biological functions of *TBX5-AS1* on NSCLC at a cellular level. Nevertheless, many other long noncoding antisense RNAs have been explored in NSCLC cells, such as actin filament-associated protein 1 antisense RNA 1 (*AFAP1-AS1*),[@cit0032] SBF2 antisense RNA 1 (*SBF2-AS1*),[@cit0033] etc. These antisense RNA both were up-regulated in NSCLC and promoted malignant phenotype of NSCLC cells. In contrast, we have shown a unique common suppression pattern of *TBX5-AS1* in NSCLC cells, compared with other antisense RNA. For example, *ZEB1* as an oncogene drives epithelial-to-mesenchymal transition, thus accordingly lncRNA *ZEB1-AS1* also acts as an oncogene by promoting malignant progression.[@cit0034],[@cit0035] We speculated that the members of the TBX family and their corresponding antisense RNA have different patterns of expression in NSCLC. *TBX5* is reported to have a tumor-suppressing effect in colon cancer and NSCLC cells.[@cit0014],[@cit0036] Predictably, overexpression of *TBX5-AS1* showed the same tumor-suppressing effect in NSCLC cells. However, the exact mechanism between *TBX5-AS1* and *TBX5* remains unclear and needed to be elucidated. In short, the present evidently demonstrated that *TBX5-AS1* acted as a tumor suppressor in NSCLC, and might have the potential to become an effective therapeutic target.

The elucidation of the downstream regulatory pathway of these lncRNAs contributes to understanding the pathogenic mechanisms of disease progression and improving the therapeutic efficiency for targeted therapy. Except for binding to microRNAs or RBPs, lncRNAs could regulate protein translation and modification directly.[@cit0037] For instance, the antisense RNA of wilms Tumor 1 Antisense RNA (*WT1-AS*) could maintain the stability and regulate the translation of WT1 mRNA.[@cit0037] Thus, we thought that *TBX5-AS1* might regulate some certain downstream gene. In previous studies, a number of antisense RNAs has been revealed to affect the cell phenotypes by modulating the PI3K/AKT pathway.[@cit0038],[@cit0039] Thus, we investigated the hypothesis that *TBX5-AS1* might regulate the PI3K/AKT pathway in NSCLC cells. As results, we found that *TBX5-AS1* overexpression suppressed the phosphorylation of PI3K and AKT, indicating that *TBX5-AS1* might inactivate the PI3K/AKT pathway. Meanwhile, the addition of PI3K activator reversed the *TBX5-AS1*-induced inactivation of the PI3K/AKT pathway and affected aggressive phenotypes of NSCLC cells. Although no similar studies have demonstrated a relationship between *TBX5-AS1* and the PI3K/AKT signaling pathway, another member of the TBX family named as TBX1 is reported to function as a tumor suppressor by inhibiting the activation of the PI3K/AKT pathway[@cit0023]. Taken together, the results could conclude that *TBX5-AS1* inhibited the aggressive phenotypes of NSCLC cells through inactivating the PI3K/AKT pathway.

Conclusion {#s0005}
==========

The present study identified that *TBX5-AS1* served as a tumor suppressor in NSCLC. We confirmed the down-regulation of *TBX5-AS1* in NSCLC patients and cell lines. Moreover, we creatively confirmed the inhibition effects of *TBX5-AS1* on aggressive phenotypes of NSCLC cells, possibly by inhibiting the activation of the PI3K/AKT pathway. The understanding of this novel biological function and mechanism for *TBX5-AS1* is conducive to elucidate the pathogenesis of NSCLC and provide a new target for the treatment of NSCLC.
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